NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
NewAmsterdam Pharma (Nasdaq: NAMS) announced it will present comprehensive Alzheimer's Disease (AD) biomarker data from its BROADWAY clinical trial at the Alzheimer's Association International Conference (AAIC) on July 30, 2025 in Toronto.
The presentation will focus on the effects of Obicetrapib, an oral CETP inhibitor, on Alzheimer's Disease biomarkers in 1,727 patients with cardiovascular disease. The company will host a webcast at 10:00 a.m. ET featuring distinguished speakers including Dr. Philip Scheltens, Dr. Kellyann Niotis, and Dr. Nathaniel Chin to discuss the findings.
NewAmsterdam Pharma (Nasdaq: NAMS) ha annunciato che presenterà dati completi sui biomarcatori della Malattia di Alzheimer (AD) provenienti dal suo studio clinico BROADWAY durante la Alzheimer's Association International Conference (AAIC) il 30 luglio 2025 a Toronto.
La presentazione si concentrerà sugli effetti di Obicetrapib, un inibitore orale della CETP, sui biomarcatori della Malattia di Alzheimer in 1.727 pazienti affetti da malattie cardiovascolari. La società terrà una webcast alle 10:00 ET con relatori di spicco tra cui il Dr. Philip Scheltens, la Dr.ssa Kellyann Niotis e il Dr. Nathaniel Chin per discutere i risultati.
NewAmsterdam Pharma (Nasdaq: NAMS) anunció que presentará datos completos sobre biomarcadores de la Enfermedad de Alzheimer (AD) de su ensayo clínico BROADWAY en la Alzheimer's Association International Conference (AAIC) el 30 de julio de 2025 en Toronto.
La presentación se centrará en los efectos de Obicetrapib, un inhibidor oral de CETP, sobre los biomarcadores de la Enfermedad de Alzheimer en 1,727 pacientes con enfermedad cardiovascular. La compañía realizará una transmisión en vivo a las 10:00 a.m. ET con destacados ponentes, incluyendo al Dr. Philip Scheltens, la Dra. Kellyann Niotis y el Dr. Nathaniel Chin, para discutir los hallazgos.
NewAmsterdam Pharma (나스닥: NAMS)는 BROADWAY 임상시험에서 얻은 알츠하이머병(AD) 바이오마커 데이터를 2025년 7월 30일 토론토에서 열리는 알츠하이머 협회 국제학술대회(AAIC)에서 발표할 예정이라고 밝혔습니다.
이번 발표에서는 심혈관 질환 환자 1,727명을 대상으로 한 경구용 CETP 억제제인 오비세트라립(Obicetrapib)이 알츠하이머병 바이오마커에 미치는 영향에 초점을 맞출 예정입니다. 회사는 오전 10시(동부시간)에 웹캐스트를 진행하며, Dr. Philip Scheltens, Dr. Kellyann Niotis, Dr. Nathaniel Chin 등 저명한 연사들이 연구 결과를 논의할 예정입니다.
NewAmsterdam Pharma (Nasdaq : NAMS) a annoncé qu'elle présenterait des données complètes sur les biomarqueurs de la maladie d'Alzheimer (AD) issues de son essai clinique BROADWAY lors de la conférence internationale de l'Alzheimer's Association (AAIC) le 30 juillet 2025 à Toronto.
La présentation mettra l'accent sur les effets de l'Obicetrapib, un inhibiteur oral de la CETP, sur les biomarqueurs de la maladie d'Alzheimer chez 1 727 patients atteints de maladies cardiovasculaires. La société organisera un webinaire à 10h00 ET avec des intervenants de renom, notamment le Dr Philip Scheltens, le Dr Kellyann Niotis et le Dr Nathaniel Chin, pour discuter des résultats.
NewAmsterdam Pharma (Nasdaq: NAMS) gab bekannt, dass es umfassende Biomarkerdaten zur Alzheimer-Krankheit (AD) aus seiner BROADWAY-Studie auf der Alzheimer's Association International Conference (AAIC) am 30. Juli 2025 in Toronto präsentieren wird.
Die Präsentation wird sich auf die Wirkung von Obicetrapib, einem oralen CETP-Inhibitor, auf Alzheimer-Biomarker bei 1.727 Patienten mit Herz-Kreislauf-Erkrankungen konzentrieren. Das Unternehmen wird um 10:00 Uhr ET ein Webcast veranstalten, bei dem namhafte Referenten wie Dr. Philip Scheltens, Dr. Kellyann Niotis und Dr. Nathaniel Chin die Ergebnisse diskutieren werden.
- None.
- None.
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th –
NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer’s Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer’s Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada.
Details of the presentation are as follows:
Presentation Title: Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer’s Disease Biomarkers in 1727 Patients with Cardiovascular Disease
Session Title: Developing Topics on Innovative Therapeutic Approaches
Presentation Date and Time: Wednesday, July 30, 2025, 8:21-8:28 AM ET
Presenter: Philip Scheltens M.D., Ph.D.
Location: Room 718
Conference Call and Webcast Information
NewAmsterdam will host a live webcast and conference call at 10:00 a.m. ET on July 30, 2025 to review the full AD biomarker data presented at AAIC. The call will include remarks from featured speakers including:
- Philip Scheltens, M.D., Ph.D., professor of Neurology at the Vrije Universiteit Amsterdam and partner and head of EQT Life Sciences Dementia Fund;
- Kellyann Niotis, M.D., director of Parkinson’s and Lewy Body Dementia Research at The Institute for Neurogenerative Diseases - Parkinson’s and Alzheimer’s Research Education Foundation; and
- Nathaniel Chin, M.D., medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC) and medical director for the Wisconsin Registry for Alzheimer's Prevention (WRAP).
To access the live webcast, participants may register here. The live webcast will be available under the “Events & Presentations” section of the Investor Relations page of the Company’s website at ir.newamsterdampharma.com.
To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam’s website following the live event.
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When will NewAmsterdam Pharma (NAMS) present its BROADWAY trial data at AAIC 2025?
What is the focus of NewAmsterdam's (NAMS) BROADWAY trial presentation at AAIC 2025?
Who are the key speakers at NewAmsterdam's (NAMS) AAIC 2025 conference call?
How can investors access NewAmsterdam's (NAMS) AAIC 2025 presentation?
